Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: A case report and review of the literature

Cytotherapy

Volumn 17, Issue 3, 2015, Pages 330-335

  Saito, Shoji ^a,b   Yanagisawa, Ryu ^a,b   Yoshikawa, Kentaro ^a,b   Higuchi, Yumiko ^a   Koya, Terutsugu ^a   Yoshizawa, Kiyoshi ^a   Tanaka, Miyuki ^b   Sakashita, Kazuo ^b   Kobayashi, Takashi ^a   Kurata, Takashi ^b   Hirabayashi, Koichi ^b   Nakazawa, Yozo ^b   Shiohara, Masaaki ^b   Yonemitsu, Yoshikazu ^c   Okamoto, Masato ^d   Sugiyama, Haruo ^e   Koike, Kenichi ^b   Shimodaira, Shigetaka ^a  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cells; ELISPOT; HSCT; Tetramer analysis; Wilms tumor 1

Indexed keywords

DENDRITIC CELL VACCINE; MESSENGER RNA; WT1 PROTEIN; CANCER VACCINE; PEPTIDE FRAGMENT; WT1 (126-134), HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER IMMUNIZATION; CASE REPORT; DEATH; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; LEUKEMIA RELAPSE; LUNG ASPERGILLOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ADVERSE EFFECTS; CHILD; CLINICAL TRIAL; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MALE; PHASE 1 CLINICAL TRIAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; SAFETY; TRANSPLANTATION; TUMOR RECURRENCE; VACCINATION;

ADOLESCENT; CANCER VACCINES; CHILD; DENDRITIC CELLS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SAFETY; T-LYMPHOCYTES; TISSUE DONORS; VACCINATION; WT1 PROTEINS;

EID: 84924958796     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.10.003     Document Type: Article

References (13)

1. Spyridonidis A., Labopin M., Schmid C., Volin L., Yakoub-Agha I., Stadler M., et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012, 26:1211-1217.
2. Kolb H.J., Schmid C., Barrett A.J., Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
3. Kitawaki T., Kadowaki N., Fukunaga K., Kasai Y., Maekawa T., Ohmori K., et al. Aphase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol 2011, 153:796-799.
4. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S., Ladell K., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010, 107:13824-13829.
5. Kimura Y., Tsukada J., Tomoda T., Takahashi H., Imai K., Shimamura K., et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012, 41:195-205.
6. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
7. Fujii S., Shimizu K., Fujimoto K., Kiyokawa T., Tsukamoto A., Sanada I., et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001, 42:357-369.
8. Kitawaki T., Kadowaki N., Kondo T., Ishikawa T., Ichinohe T., Teramukai S., et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol 2008, 83:315-317.
9. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004, 101:13885-13890.
10. Keilholz U., Letsch A., Busse A., Asemissen A.M., Bauer S., Blau I.W., et al. Aclinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
11. Rezvani K., Yong A.S., Savani B.N., Mielke S., Keyvanfar K., Gostick E., et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007, 110:1924-1932.
12. Tyler E.M., Jungbluth A.A., O'Reilly R.J., Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013, 121:308-317.
13. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100:2132-2137.